title: An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function.
abstract: We describe the production and biochemical characterization of the first GPIIb/IIIa-inhibiting monoclonal antibody that contains an RGD sequence in the CDR3 region of the heavy chain. Monoclonal antibodies obtained by immunizing mice with human platelets were screened using consecutive ELISAs based on human platelets and immuno-affinity-purified glycoprotein (GP) IIb/IIIa coated on microtitre plates. Out of 30 monoclonal antibodies reacting with GPIIb/IIIa, one, MA-16N7C2, potently inhibited platelet aggregation induced by ADP, thrombin, arachidonic acid, collagen, U46619, adrenaline and platelet-activating factor, whereas ristocetin-induced aggregation was unaffected. MA-16N7C2 (IgG2a) bound approximately 4 times faster to activated than to resting platelets, with a Kdcalc of 6.6nM and of 17.5nM, respectively. Equilibrium binding studies to non-activated platelets showed a Kd of 18.2nM with 41 x 10(3) binding sites per platelet. The antibody recognized GPIIb/IIIa only as a Ca(2+)-dependent complex. MA-16N7C2 blocked fibrinogen and von Willebrand factor binding to GPIIb/IIIa in a competitive manner with a Ki of 8.5nM and 13.2nM, respectively. Sequence analysis revealed a RGD-containing sequence with homology to disintegrins, in the CDR3 region of the heavy chain. That this RGD-containing sequence could be involved in the interaction of the antibody to GPIIb/IIIa was finally indicated by showing that the binding is completely and competitively inhibited by echistatin.
authors.affiliation: Centre for Molecular and Vascular Biology, K.U. Leuven, Belgium.
authors.forename: H
authors.initials: H
authors.lastname: Deckmyn
authors.forename: P
authors.initials: P
authors.lastname: Stanssens
authors.forename: B
authors.initials: B
authors.lastname: Hoet
authors.forename: P J
authors.initials: PJ
authors.lastname: Declerck
authors.forename: M
authors.initials: M
authors.lastname: Lauwereys
authors.forename: Y
authors.initials: Y
authors.lastname: Gansemans
authors.forename: I
authors.initials: I
authors.lastname: Tornai
authors.forename: J
authors.initials: J
authors.lastname: Vermylen
mesh_terms: D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000378:metabolism; D001483:Base Sequence; D001665:Binding Sites; D001792:Blood Platelets / Q000276:immunology / Q000378:metabolism; D015153:Blotting, Western; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000276:immunology / Q000378:metabolism; D016023:Integrins / Q000378:metabolism*; D036341:Intercellular Signaling Peptides and Proteins; D008969:Molecular Sequence Data; D010455:Peptides; D010974:Platelet Aggregation; D010975:Platelet Aggregation Inhibitors / Q000378:metabolism*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors*; D014757:Viper Venoms / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D007143:Immunoglobulin Heavy Chains; D016023:Integrins; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D014757:Viper Venoms; C057986:echistatin